IPSIndian Journal of Pharmacology
Home  IPS  Feedback Subscribe Top cited articles Login 
Users Online : 96 
Small font sizeDefault font sizeIncrease font size
Navigate Here
  Search
 
 » Next article
 » Previous article 
 » Table of Contents
  
Resource Links
 »  Similar in PUBMED
 »  Search Pubmed for
 »  Search in Google Scholar for
 »Related articles
 »  Article in PDF (310 KB)
 »  Citation Manager
 »  Access Statistics
 »  Reader Comments
 »  Email Alert *
 »  Add to My List *
* Registration required (free)

 
In This Article
 »  Abstract
 »  Introduction
 »  How do PPARs wor...
 »  What are the phy...
 »  Pharmacological ...
 »  Pharmacological ...
 »  Conclusion
 »  References
 »  Article Figures
 »  Article Tables

 Article Access Statistics
    Viewed7511    
    Printed469    
    Emailed12    
    PDF Downloaded782    
    Comments [Add]    
    Cited by others 14    

Recommend this journal

 


 
EDUCATIONAL FORUM
Year : 2006  |  Volume : 38  |  Issue : 4  |  Page : 243-253
 

The role of peroxisome proliferator-activated receptors in human disease


Department of Pharmacology, Institute of Pharmacy, Nirma University of Science and Technology, Sarkhej-Gandhinagar Highway, Ahmedabad, India

Correspondence Address:
J A Patel
Department of Pharmacology, Institute of Pharmacy, Nirma University of Science and Technology, Sarkhej-Gandhinagar Highway, Ahmedabad
India
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/0253-7613.27020

Rights and Permissions

 » Abstract 

Increasing attention has been focused on the role of peroxisome proliferator-activated receptors (PPARs) in the past decade. Compelling data have begun to unite work from various arenas, such as epidemiology and vascular biology. Clinical trials with synthetic PPAR agonists have exhibited therapeutic benefits in treating various chronic diseases like atherosclerosis, diabetes mellitus and cardiovascular diseases. The PPARs, a family of nuclear receptors (NRs), are a set of three receptor sub-types encoded by distinct genes. They function as lipid sensors to regulate a broad range of genes in many metabolically active tissues. The discovery of PPAR-specific ligands has led to a significant advancement in our understanding of the structure of these receptor proteins and molecular mechanisms of their ligand dependent activation. Herein, we have tried to delineate the role of PPARs as molecular targets for the development of new drugs to treat human metabolic diseases.


Keywords: PPARs, PPAR ligands, nuclear hormone receptor, metabolic diseases.


How to cite this article:
Javiya V A, Patel J A. The role of peroxisome proliferator-activated receptors in human disease. Indian J Pharmacol 2006;38:243-53

How to cite this URL:
Javiya V A, Patel J A. The role of peroxisome proliferator-activated receptors in human disease. Indian J Pharmacol [serial online] 2006 [cited 2021 Aug 3];38:243-53. Available from: https://www.ijp-online.com/text.asp?2006/38/4/243/27020



 » Introduction Top


Nuclear hormone receptors (NR) are ligand activated transcription factors that regulate gene expression in response to small lipophilic compounds. The well known members of this NR family are testosterone receptor [androgen receptor (AR)], oxysterols receptor [liver X receptor (LXR)], estrogen receptor (ER), xenobiotics receptor [pregnane X receptor (PXR)], retinoic X receptor (RXR), thyroid hormone receptor (TR), bile acids receptor [farsenoid X receptor (FXR)] and vitamin D receptor (VDR).

The peroxisome proliferator-activated receptors (PPARs) comprise an important subfamily of the NR superfamily that plays a central role in the regulation of storage and catabolism of dietary fats.[1],[2],[3] The three subtypes of PPAR (alpha, delta and gamma) bind to fatty acids (FAs) and fatty acid metabolites and regulates the expression of genes involved in the transport, metabolism and buffering of these ligands with cells. Each of the three PPAR subtypes exhibits a unique expression pattern within vertebrate tissues.

PPARa are more widely expressed in brown adipose tissue, skeletal muscle, heart, liver and kidney than PPARg (white and brown adipose tissues, muscle, colon and liver).[2] Besides, both PPARa and g are expressed in the major cellular constituents of the vessel wall (endothelial cells, vascular smooth muscle cells (VSMC) and monocytes/macrophages) as well as human atherosclerotic lesions.[4] PPARd exhibits wide tissue distribution and is found in all tissues studied to date.[2]


 » How do PPARs work at the molecular level? Top


PPARs possess the canonical domain structure of other NR superfamily members. The functional domains of the PPARs consist of poorly characterised N-terminal region that contain a potential trans-activation function known as activation factor-1 (AF-1), DNA-binding domain (DBD) and ligand binding domain (LBD). Molecular modeling reveals that DBD and LBD, at carboxyl terminus, is a large hydrophobic pocket, which contains a key, ligand dependent trans-activation function called activation factor-2 (AF-2). As described in [Figure - 1], PPARs bind to cognate DNA elements called PPAR response elements (PPREs) in the 5'-flanking region of target genes. Like many other NRs, they bind DNA as obligate heterodimers by partnering with one of the retinoid X-receptors. Known PPREs are direct repeats of all AGGNCA half site separated by a one base pair spacer.

A short sequence located immediately upstream of the first half site confers polarity on the PPREs, with the PPAR moiety binding 5' to the RXR half of the heterodimer. But many cell types express more than one PPAR isoform. So most likely isoform specific targets are regulated through a combination of subtle cis-sequence differences flanking the core response element, the presence of specific or selective co-activator proteins and regulation of endogenous ligands.[5]

Like other NRs, PPARs form protein-protein interaction with a variety of nuclear proteins known as co-activators and co-repressors, which mediate contact between the PPAR-RXR heterodimer, chromatin and basal transcriptional machinery, which also promotes activation and repression of gene expression respectively. Co-activator proteins promote the early stage of transcription and fall into three categories.

1. Protein with histone acetylase activity which remodels chromatin structure (e.g. SRC-I, CBP).

2. Members of the DRIP/TRAP complex which interact with basal transcription architecture (e.g. PBP/TRAP220).

3. Proteins with incompletely defined function (e.g. PGCI, RIP 140).[6]

There are no known receptor specific co-activators or co-repressors, although selectivity for one or the other NR has been illustrated in certain cases and thus may form the basis for tissue specific targets of certain NR ligands.[7],[8] Co-activator proteins either possess or recruit histone acetyl transferase (HAT) activity to the transcription initiation site. Acetylation of histone protein is believed to relieve the tightly packed structure of the chromatin allowing the RNA polymerase II complex to bind and initiate transcription. Co-activators also recruit the chromatin remodeling SWI-SNF complex to target promoters.[3], [5], [9]


 » What are the physiological roles played by PPARs? Top


PPARα

PPARa was cloned early in 1990s. It plays an important role in the oxidation of fatty acids in the liver. Receptor activation stimulates fatty acid oxidation such as in fasting, which is a crucial adaptive response to nutritional challenge. PPARa is highly expressed in tissues with high rates of fatty acid catabolism. This receptor regulates genes that control fatty acid uptake, causes activation of acyl CoA esters and degradation by way of peroxisomal and mitochondrial β-oxidation pathways. PPARa activators reduce the quantities of available fatty acids for triglyceride rich very low density lipoprotein (VLDL) synthesis in the liver. So, physiological role of PPARa receptor is to sense the total flux of dietary fatty acids in key tissues.[10]

PPARα ligands

PPARα binds to a diverse set of ligands, namely, arachidonic acid metabolites (prostaglandins and leukotrienes), plasticisers and synthetic fibrate drugs such as bezafibrate, fenofibrate, clofibrate and gemfibrozil.[10] More recent thioisobutyric acid compounds (GW 7647, GW 9578) show excellent selectivity for PPARα receptors.[11],[12] Recently reported LY518674 is a novel selective PPARa agonist.[13]


 » Pharmacological role of PPARa agonists in human disease Top


Dyslipidemia

Lipid homeostasis imbalance has been linked to cardiovascular diseases. In addition to obesity, insulin resistance and hypertension are co-morbidities associated with dyslipidemia. In particular, lowering plasma triglycerides (TGs) and elevating high density lipoprotein cholesterol (HDLc) are of vital importance in reducing diabetic cardiovascular risk. The fibrates are a class of lipid lowering drugs that mediate their clinical effects primarily through activation of PPARα.[14],[15]

Evidence from studies in rodents and humans implicate 5 major mechanisms underlying the modulation of lipoprotein phenotypes by fibrates.

1. Induction of lipoprotein lipolysis: Increased triglyceride-rich lipoprotein (TRLs) lipolysis could be a reflection of change in intrinsic lipoprotein lipase (LPL) activity or increased accessibility of TRLs for lipolysis by LPL owing to a reduction of TRL apoC-III content.

2. Induction of hepatic fatty acid (FA) uptake and reduction of hepatic triglyceride production: In rodents, fibrates increase FA uptake and conversion to acyl-CoA by the liver owing to the induction of FA transporter protein (FATP) and acyl-CoA synthetase (ACS) activity. Induction of the b-oxidation pathway and w-oxidation (Cytochrome P450) pathway with a concomitant decrease in FA synthesis by fibrates results in a lower availability of FAs for triglyceride synthesis, a process that is amplified by the inhibition of hormone-sensitive lipase in adipose tissue by fibrates.

3. Increased removal of LDL particles: Fibrate treatment results in the formation of LDLc with a higher affinity for the LDL receptor, which are thus catabolised more rapidly.

4. Reduction in neutral lipid (cholesteryl ester and triglyceride) exchange between VLDL and HDLc may result from decreased plasma levels of TRL.

5. PPARa activation influences the expression of five key genes encoding for proteins involved in HDLc metabolism. The fibrate class of PPARa agonist has been shown to increase HDLc synthesis through interaction of gene encoding for apolipoprotein A-I, apolipoprotein A-II and lipoprotein lipase. In addition, PPARa activators increase 'reverse cholesterol transport' by accelerating the efflux of cholesterol from peripheral cells and increasing its uptake into liver through a pathway involving increased vascular expression of the HDLc receptors, ATP-binding cassette transporter-I (ABC-I) and scavenger receptor class-B type-I (SR-BI).

The overall effect of PPARa activation on lipid profile is achieved through increased HDLc synthesis, accelerated cholesterol efflux and hepatic uptake, which enhances the HDLc protective effect providing significant clinical benefit.[2], [3], [9], [16]

Atherosclerosis

PPARα agonist affects a range of biological processes which contribute to the etiology of coronary artery disease. For instance, expression of VCAM-I (Vascular Cell Adhesion Molecule-I), an adhesive protein which recruits monocytes to endothelial cells at sites of vascular inflammation or atherosclerotic lesions, is downregulated by PPARα agonist in endothelial cells studies.[6]

PPARα is expressed in atherosclerotic plaque and primary culture of smooth muscle cells, macrophages as well as endothelial cells. This inflammatory process can be inhibited by control of proatherogenic gene transcription induced by NF-kB (Nuclear Factor- kappa B).[7] Additionally, PPARα ligands induce apoptosis of macrophages activated with TNFα or γ-Interferon.[8]

Lipid homeostasis is controlled in part by the nuclear receptor PPARa and LXR through regulation of genes involved in fatty acid and cholesterol metabolism. Further, recent reports[17],[18] state that pharmacological manipulation of LXRa agonism by PPARa ligands may provide a novel way to exploit the ability of LXR ligands to prevent/treat dyslipidemia and atherosclerosis.

PPARα increases the production of the apolipoproteins, apo-AV, apo-CIII, which results in decreased level of TGs in the circulation. Thus, activation of PPARα reduces the TG content in liver and circulation exactly the reverse of the effects of LXRα activation. Some of the PPARα agonists also slightly increase HDLc in humans, thus working in the same directions with the LXRα agonist. These results indicate that co-administration of PPARα agonist may be helpful in eliminating or reducing a significant unwanted effects of LXRα agonists, hypertriglyceridemia. While it may enhance their beneficial effects on the vasculature by increasing HDLc and enlarging HDL particles.[17],[18]

Obesity

Obesity is a risk factor in the development of diabetes and fibrate treatment has been reported to reduce weight gain in rodents. Bezafibrate,[19] Wy-14643[20] and other agents[21],[22] induce genes involved in increased energy expenditure of fatty acid catabolism.

Diabetes

Given that these agents have exhibited improved insulin action and glucose utilisation in both high fat fed C57BL6 mice and obese zucker rats, the data suggest that PPARa ligands can reduce insulin resistance without significant effects on adipose mass accumulation.[3]

PPARγ

PPARγ has been the most extensively studied PPAR subtype to date. Two distinct N-terminal isoforms termed as PPARγ1 and PPARγ2 have been identified in mice and humans.[23],[24]

PPARg is a pivotal transcription factor in the regulation of adipocyte gene expression and differentiation. The regulation of adipocyte differentiation by PPARγ involves a coordinated signaling cascade with other families of transcription factors. In addition to adipogenic effects, PPARg has been shown to be an important regulator of target genes involved in glucose and lipid metabolism. [Table - 1] PPARg agonists are efficacious antidiabetic agents. PPARγ agonists may also have therapeutic utility in the treatment of other conditions like atherosclerosis, inflammation and cancer.[1]

PPARγ ligands

Ligand studies have shown numerous naturally occurring fatty acids, eicosanoids, prostaglandins and their metabolites to be weak endogenous activators of PPARg. PPARγ exhibits modest preference for essential polyunsaturated fatty acids (PUFAs) including linoleic, linolenic, arachidonic and eicosapentaenoic acids. Thus, PPARγ may serve as a generalised fatty acid sensor that couples changes in overall PUFAs' concentration with the target genes associated with lipid and glucose homeostasis.[3]

Synthetic agonists

The thiazolidinedione (TZD) class of antidiabetic agents commonly referred to as glitazones' represent the first compounds identified as high affinity PPARg agonists such as rosiglitazone, pioglitazone etc. A series of tyrosine based PPARg agonists G1262570 (farglitazar), GW 1929 and GW 7845,[25],[26],[27] the isoxazolidinedione JTT- 501,[28] the TZD analogue KRP-297[29] have been some of the recently developed compounds showing promising anti-diabetic activity in animal studies.

Selective PPARγ modulators

Clinical benefits of PPARγ agonists in treating type-2 diabetes has been clearly demonstrated, but the problem associated with current generation of glitazone drugs is that they are associated with undesirable side effects such as weight gain and edema.

Thus, it was of significant interest to design PPARγ modulator, which retains efficacious insulin sensitising properties while minimising potential adverse effects. GW 0072 (non TZD thiazolidine acetamide) antagonises the adipocyte differentiation induced by rosiglitazone but promotes adipocyte differentiation in the presence of insulin and, hence, functions as insulin sensitiser.[30],[31] It can inhibit the adipogenic effects of rosiglitazone but not insulin, without inducing much weight gain. Glitazones MCC-555 (netoglitazone) and NC-2100 represent a second class of PPARγ modulators.[32],[33]

Antagonist

Recently, many irreversible PPARγ antagonist ligands have been identified namely GW9662, T0070907, PD068235, LG100641, BADGE and so on.[34] These PPARg antagonists block adipogenesis induced by either rosiglitazone or insulin by inhibiting transcriptional activity and co-factor association induced by rosiglitazone. GW9662 was recently identified as irreversible PPARγ antagonist ligand. It acts as PPARg antagonist at concentration of 1-10 µM in cell-based assay. It binds covalently to the Cys 286 gene, located on helix three of the PPARg ligand-binding domain. It displays greater affinity for PPARg than for PPARa or PPARd although this cysteine residue is conserved in all three PPAR subtypes. It antagonises PPARa activation in multiple cell lines including adipocytes, macrophages and hepatic stellate cells.[34],[35],[36],[37]

The ligand LG100641 has been described as a specific antagonist that inhibits rosiglitazone induced adipocyte differentiation but stimulates insulin mediated glucose uptake in adipocytes.[38] The plasticizer BADGE blocks both rosiglitazone and insulin induced adipogenesis but requires concentrations that approach its limit of solubility.[3] The PPARγ ligand CDDO-Me is a synthetic triterpenoid that has been shown to inhibit adipocyte differentiation at concentration below 1 µM.[3]


 » Pharmacological role of PPAR γ agonists in human disease Top


Diabetes

The treatment of type-2 diabetes is the most widely studied therapeutic utility for a PPARγ agonist. PPARγ agonists reduce plasma glucose, lipid and insulin levels in type-2 diabetes.[39],[40]

TZDs are the new class of drugs useful in the treatment of type-2 diabetes. Recent advances include the discovery of novel genes that are regulated by PPARγ, which helps explain how activation of this adipocyte predominant transcription factor regulates glucose and lipid homeostasis. Increased levels of circulating free fatty acids (FFAs) and lipid accumulation in nonadipose tissue have been implicated in the development of insulin resistance. This situation is improved by PPARg ligands which promote fatty acid storage in fat depots and regulate the expression of adipocyte secreted hormones that impact on glucose homeostasis.

Adiposa is a major target tissue of insulin sensitising PPARg ligands. However, improved glucose homeostasis related to administration of PPARg ligands such as TZDs involves insulin sensitisation in muscle and liver, which raised the paradoxical question, "How does a receptor, expressed predominantly in adipose tissues, improve glucose metabolism in muscle?"[41] TZDs suppress insulin resistance in adipose tissue in addition to skeletal muscle and liver, which contain low concentration of PPARg. Adipose tissues function as an endocrine organ. PPARγ ligand increases the expression of cell surface receptors such as fatty acid protein transporter (FATP), CD36 and others, which results in trapping and uptake of FFA in adipocytes. In addition to increased FFA flux into adipocytes, FFA efflux is reduced by the expression of genes which promote the storage of FFAs in the form of TGs, by increasing production of glycerol-3-phosphate. The PPARγ ligand also expresses other genes which are necessary for triglyceride synthesis such as phosphenolpyruvate carboxykinase (PEPCK), glycerol kinase (GyK) and so on. [Table - 1]

Consequently, lipid levels in adipose tissue rise whereas circulating FFAs diminish.[42] So, by repartitioning lipid away from liver and muscle, PPARγ agonists ameliorate hyperglycemia, by reversing lipotoxicity induced insulin resistance. Data from patients with type-2 diabetes mellitus and preclinical studies also demonstrate that PPARγ agonists function as 'adipose remodeling factors' that redistribute lipids from insulin-resistant, lipolytic visceral-fat depots into subcutaneous fat that contains small, newly differentiated, insulin-responsive adipocytes .

Adipocyte-derived leptin is a circulating regulator of appetite and energy expenditure. Adiponectin and resistin are additional adipocyte-specific secreted proteins which appear to have a role in insulin sensitivity as do other polypeptides which are secreted non-exclusively by adipocytes, including TNFa, plasminogen activator inhibitor 1 (PAI-1) and IL-6. TZDs repress adipocyte gene expression of resistin, TNFa and IL-6, all of which have been implicated in insulin resistance. Furthermore, TZDs decrease adipocyte secretion of PAI-1, a prothrombotic which is increased in obesity. Moreover, PPARγ ligands induce gene expression of adiponectin, insulin sensitising adipocyte hormone. Remarkably, gene regulation as a result of TZDs treatment alters many, if not all, of these adipose derived endocrine factors. Overall, therefore, PPARγ ligands alter the expression of several adipocyte hormones in a manner that is likely to mitigate insulin resistance.[41]

PPARγ ligands regulate the expression of several other genes that enhance glucose metabolism in the adipocyte, including those which encode the insulin responsive glucose transporter GLUT4, GLUT2 and c-Cbl associating protein (CAP) (crucial for GLUT4 translocation to the surface). By this way, they increase glucose uptake into tissue and decrease overall glucose. Overexpression of 11β-HSD1 (11β-hydroxy steroid dehydrogenase1) in adipocytes cause insulin resistance, suggesting that reduction of adipocyte 11β-HSD1 might promote insulin sensitivity, either by reducing glucocorticoid induced gene expression in the adipocyte or by reducing adipocyte secretion of glucocorticoids. Any or all of these effects might contribute to the smaller adipocyte size that is associated with PPARγ activation. It has been reported that smaller adipocytes typically have greater insulin sensitivity, take up more glucose and have lower rates of lipolysis compared to large adipocytes.[3],[43],[44]

Atherosclerosis

The progression of atherosclerosis involves the accumulation of foam cells underneath the arterial wall endothelium. Foam cells are cholesterol laden macrophages which result from the internalisation of oxidised LDL (oxLDL) particles by lipid transporters such as CD36, SR-A and others.[45],[46] The abundant expression of PPARγ might seem that PPARg is proatherogenic by promoting foam cell formation. However, using a standard model of atherosclerosis Li et al[46] had demonstrated that the treatment of LDLc receptor deficient mice with rosiglitazone or GW 7845 was shown to prevent the formation of atherosclerotic lesions despite increasing CD36 expression. Several studies have found that the PPARg agonist (troglitazone) decreased atherosclerosis when given to either LDLc receptor or apolipoprotein E receptor deficient mice.[47] In addition, previous clinical data indicates that PPARγ agonist (troglitazone) actually protects type-2 diabetic patients from atherosclerosis.[48]

A recent study has provided insight into the antiatherogenic effects of PPARg. ABCA-I is a member of the ATP binding cassette family of energy dependent transporter proteins which regulates cholesterol efflux from macrophages. ABCA-I gene expression is regulated by the nuclear oxysterol receptor LXR. PPARγ activation induces the expression of LXR, which promotes ABCA-I expression and ultimately cholesterol efflux.[49],[50] Thus, PPARγ may be antiatherogenic in vivo by enhancing cholesterol efflux from macrophages and endothelial cells.

In vitro , animal model and clinical studies indicate that TZDs:

l Correct endothelial dysfunction.

l Suppress chronic inflammatory processes.

l Reduce fatty acid formation.

l Delay plaque evolution and vessel wall thickening.

l Enhance plaque stabilisation and regression.

Thus, TZDs show potential as potent antiinflammatory, antithrombotic agents which could improve glucose tolerance and the long-term cardiovascular risk related to atherosclerosis in patients with type-2 diabetes.[51]

Inflammation

Several investigators have established PPARg expression in monocytes/macrophages and human atherosclerotic lesions.[50],[52],[53] Jiang et al [54] found that PPARγ agonists decreased production of tumor necrosis factor-α (TNF-α), interleukin-1β and interleukin-6 by phorbol 13-myristate 12 acetate, but not lipopolysaccharide stimulated monocyte like cell lines. Ricote et al [55] found that PPARg activators decreased the promoter activity for genes such as inducible nitric oxide synthase and matrix metalloproteinase-9 (gelatinase-β). Rosiglitazone, a PPARγ agonist, was found to be a potent antiinflammatory agent in animal models of acute inflammation.[56] In vitro reports find PPARγ inhibition of monocyte chemoattractant protein-I directed chemotaxis. PPARg agonists also inhibit chemokines (interleukin-8) in epithelial cells, leading to the suggestion of their use in inflammatory bowel diseases.[3]

Cancer

PPARg is highly expressed in several human cancer cell lines, including liposarcoma,[57] breasts,[58] colon,[59] lungs,[60],[61] prostate,[62] bladder[63] and gastric.[64] The PPARg agonists such as TZDs and 15d-prostaglandin J 2 (15d-PGJ- 2 ) have demonstrated not only apoptosis and growth inhibition of numerous cancer cell lines in vitro , but have also shown tumour growth suppression in vivo rodent carcinoma models.[65],[66] Promising phase 2 clinical trials, with troglitazone, suggest that the use of these agents offer an improved therapeutic treatment opportunity for inoperable lipocarcinomas.[67]

PPARd

Human PPARδ was cloned in the early 1990s.[68] Understanding the biological function of PPARδ, however, has been impeded due to its ubiquitous expression, absence of potent and selective ligands and the lack of connection of clinical disorders. However, growing evidence suggests that PPARd plays a role in lipid metabolism, cholesterol efflux,[69] adipogenesis,[70] colon cancer,[71] bone metabolism,[72] embryo implantation[73] and development of brain and skin.[74],[75]

PPARd ligands

The 4-thiosubstituted phenoxyacetic acids GW501516,[69] GW0742[76] are potent and selective PPARδ agonists. Merck has also reported phenoxyacetate L-165041[77] and a series of 4-[(aryloxy) propyl thio] phenyl acetate based agents as agonists of PPARd.[78]

Pharmacological role of PPARd agonists in human diseases

Lipid metabolism and holesterol efflux: PPARδ selective ligands have been reported to increase HDLc in diabetic db/db mice without effects on blood glucose and triglyceride concentration.[79]

A potent ligand, GW501516, has been shown to induce substantial dose dependent increase in HDLc while lowering LDLc, TGs and insulin levels in insulin resistant middle aged obese rhesus monkeys.[69]

Adipogenesis

PPARd may also play a role in adipocyte differentiation. A recent evaluation of the role of PPARd in adipogenesis has revealed that over expression of PPARd in NIH-3T3 fibroblasts, in the presence of cAMP elevating agents, induces PPARγ2 expression and terminal adipocyte differentiation. However, the PPARd selective agonist L-165401 only produces modest terminal differentiation in synergy with cAMP elevating agents in 3T3-L1 preadipocytes.[70] Studies have shown that PPARd deficient mice are smaller and leaner with increased expression levels of fatty acid translocase protein (CD36/FAT) in adipose tissues.[74] The same studies have shown that independent PPARδ activation is insufficient to drive terminal adipocyte differentiation, but does promote PPARγ gene expression, which upon specific ligand activation promotes adipogenesis.

Colorectal cancer

PPARd has been implicated as a direct target and potential oncogenic effector of β-catenin in colorectal carcinogenesis in mice.[80] NSAIDs such as sulindac can antagonise PPARδ activated gene transcription and reportedly suppress colorectal tumorigenesis.[81] This suggests that NSAIDs may inhibit tumour formation by blocking PPARδ activation. Additional studies, employing genetically manipulated human colon cancer cells, have demonstrated that PPARd null cells exhibit decreased tumorigenesis in nude mice compared to PPARd+/- and wild type controls.[81] This evidence suggests that PPARδ expression may promote tumour growth and thus may be a potential target for the treatment of colorectal cancer.

Bone metabolism

Mature osteoclasts modulate bone resorption activity. High expression of PPARδ has been identified in mouse and rabbit osteoclasts. The PPARd agonist carbaprostacyclin induces bone-resorbing activity. Osteoclastic genes, including cathepsin K and carbonic anhydrase type II, are also significantly up regulated. These results suggest that PPARd may play a key role in osteoclastic bone resorption and PPARδ antagonists may have potential utility in treating osteoporosis.[82]

Role of PPARs in CNS

In contrast to normal astrocytes, the cell lines of malignant astrocytoma express higher levels of PPARg. This finding tempted scientists to explore the role of PPARs in glial tumours of the brain. Incubation of malignant astrocytoma cell lines with PPARg agonists, ciglitazone and 15d-PGJ 2 , reduced cell viability and increased apoptotic rate. This may suggest the role of PPAR in regulation of the apoptotic process of astroglial cells.[83] Other studies also demonstrated that ligands of the PPARγ induce apoptosis in activated T-lymphocytes and exert antiinflammatory effects in glial cells. Preclinical studies have shown that the TZD pioglitazone delays the onset and reduces the severity of clinical symptoms in experimental autoimmune encephalomyelitis in animal model of multiple sclerosis. Supporting the above observations, Pershadsingh et al [84] reported that daily treatment with pioglitazone (45 mg) for 3 years induced apparent clinical improvement, without adverse events in a patient with secondary progressive multiple sclerosis.

PPARγ agonist and pan agonist treatment accelerated the differentiation of oligodendrocyte in mixed glial cultures. It implies that PPARγ plays a significant role in the maturation of oligodendrocyte and regulates the size of oligodendrocyte sheets. The above findings suggest that PPARγ increases the survival of cells and/or prevents cell death in the enriched culture. However, the role of PPARg as a factor in the transcriptional regulation of oligodendrocyte differentiation still needs to be investigated.[85]

Dual PPAR (α and γ) and Pan PPAR Co-agonism

Diabetic patients are prone to increased risk of coronary heart disease that stems from cardiovascular risk factors such as dyslipidemia, coagulopathy, hypertension and obesity. The hallmark problems of hyperglycemia and insulin resistance are also contributing factors. In general, PPARγ agonists, the antihyperglycemic agents, provide minimal protection against the eventual cardiovascular risks which develop with type-2 diabetes.[86] These dual-acting PPAR agonists are a novel group of compounds which also activate nuclear transcription factors. The examples are muraglitazar,[87] farglitazar, ragaglitazar, reglitazar, tesaglitazar,[3] LSN 862,[88] LY 929[89] and so on. By activating both PPARα and PPARγ receptors, they simultaneously reduce atherogenic triglycerides, raise cardioprotective HDL levels and improve insulin resistance. Thus, they address many of the core features seen in people with metabolic syndrome and may help to reverse the underlying disease process and its adverse clinical sequelae, which includes cardiovascular disorders (CVD) and diabetes. Furthermore, the stimulation of lipid catabolism by PPARa activation may offset PPARg induced adipogenesis and thereby diminish the undesired side effect of adiposity that arises from selective PPARg stimulation.[3] Recently, the first dual-PPAR agonist, muraglitazar, has been approved by the US Food and Drug Administration (FDA) advisory committee. However, Nissen et al [87] have reviewed the clinical trial documents and reported a high incidence of cardiovascular complications and death following muraglitazar administration when compared with placebo or pioglitazone.

The modification at the N-alpha position of the tyrosine-based PPARg agonist farglitazar led to the discovery of GW9544, a dual PPARa/g agonist with sub-nanomolar potency at PPARγ.[12] Studies of novel, PPARα/γ acting a-ethoxyphenylacetic acids have furnished the Phase III antidiabetic agent ragaglitazar (NN-622). Ragaglitazar exhibits better plasma glucose and triglyceride reduction than rosiglitazone in insulin resistant db/db mice.[90] Tesaglitazar (Galida), another a-ethoxyphenylacetic acid based PPARα/γ ligand, appears to improve macrophage export of cholesterol to HDL. The compound increases the reduced HDL-mediated cholesterol efflux to control levels in human, fat exposed monocyte THP-1 cells differentiated into macrophages. Tesaglitazar is poised to enter Phase III clinical trials as it has potential for the treatment of glucose and lipid abnormalities associated with type-2 diabetes and the metabolic syndrome.[3],[91] BMS-298585 is an oxybenzylglycine with potent and selective, balanced PPARα and γ agonist effects.[3]

However, safety will be a critical issue with this new class of drugs as several promising candidates have already failed because of adverse toxicity profiles. Adverse effects, seen with some dual-acting PPAR agonists in advanced-stage development, have included oedema, raised levels of hepatic enzymes and tumours in rodents. The casualties include ragaglitazar, reglitazar and, most recently, MK-767, the development of which has been discontinued.[91]

The old and well-known lipid-lowering fibric acid derivative bezafibrate is the first clinically tested pan (a, b/d and g) PPAR activator . It is a sole pan PPAR activator with more than a quarter of a century of therapeutic experience with a good safety profile. Therefore, bezafibrate could be considered as a prototype of a clinically tested pan-PPAR ligand. In patients, with relevant metabolic abnormalities, it is expected to improve both insulin sensitivity and the blood lipid profile and probably reduces the risk of long-term cardiovascular complications. In addition, we can expect prevention of overweight development due to its PPARb/d properties.[92] Recently, GSK and Plexxikon Inc. discovered the novel pan agonists, GW 67795[89] and PLX 204[89] which, besides having a and g dual agonistic activity, also possess d activity. This a, g and d agonistic activity demonstrates highly significant improvement in lipid metabolism. The pan PPAR activator DRL 11605[93] was discovered under Dr. Reddy's drug discovery programme, wherein the molecule completed its pre-clinical trials and later on was transferred to Perlecan Pharma, Canada, which has commenced Phase I clinical trials.

Toxicity related to PPARs

The role of PPAR ligands has been well established in some very important therapeutic areas such as diabetes, obesity, cardiovascular diseases, inflammation and so on. But, more recently, it is becoming clear that they are also involved in carcinogenesis. Recently, troglitazone showed liver toxicity and hence was pulled out from the market.[94] Dr. Reddy's ragaglitazar, when studied for long-term rodent toxicity, revealed that it was associated with bladder cancer. Merck, which has a compound from Japan's Kyorin, pulled it out when another rare cancer showed up in long-term rodent studies. Guidelines recently issued by FDA require that clinical trials of PPAR ligands of greater than 6 months duration be preceded by 2-year carcinogenicity studies in rodents. Although this regulatory change introduces significant delay and complexity into the development of new PPAR agents, work in this area appears to continue unabated.[42] Whether PPAR ligands produce toxicity via a receptor-dependent and/or off-target mediated mechanism is not yet known.

It is believed that increase in oxidative stress and proliferation (by decreasing the rate of apoptosis) due to activation of peroxisome proliferators (PPs) by ligand binding to PPAR alpha leads to hepatocellular adenoma and carcinoma in rodents. However, there is no evidence that humans are at any increased risk of liver cancer after chronic activation of PPs by PPAR alpha. Epidemiological studies have not revealed any risk of liver cancer development in patients chronically exposed to the widely used hypolipidemic agents gemfibrozil and clofibrate,[83] i.e. humans appear to be resistant to the induction of peroxisome proliferation and the development of liver cancer by fibrate drugs. The molecular basis of this species difference is not known. To examine the mechanism determining species differences in PPAR response between mice and humans, a PPAR-alpha humanised mouse line was generated in which the human PPAR-alpha was expressed in liver under control of tetracycline responsive regulatory system. The PPAR-alpha humanise and wild-type mice responded to treatment with the potent PPAR-ligand WY-14643 as revealed by induction of genes encoding peroxisomal and mitochondrial fatty acid metabolizing enzymes and resultant decrease of serum TG. However, surprisingly, only the wild type mice and not the PPAR-humanised mice exhibited hepatocellular proliferation, as revealed by elevation of cell cycle control genes and hepatomegaly.

These studies established that following ligand activation, the PPAR-mediated pathways controlling lipid metabolism are independent from those controlling the cell proliferation pathways. These findings also suggest that structural differences between human and mouse PPAR are responsible for the differential susceptibility to the development of hepatocarcinomas observed after treatment with fibrates. Studies reveal that the human PPAR, which has been isolated, has four amino acid differences or lacks axon 6 (alternate RNA splicing) from the wild-type sequence. Whether and how these mutants act as dominant-negative repressors of peroximal and/or lipid homeostasis gene expression are unknown. Hence, the extensive information which has accumulated on the mechanism of PP action in rodents, and the response of humans to these compounds, has yet to provide a definitive explanation for species differences. It is unlikely that a single receptor alone will elicit such a complex pleiotropic response but likely, rather, that other mediators are required for the changes in growth, lipid perturbation and peroxisome proliferation. Genes associated with cell survival and proliferation, such as TNF alpha, is under investigation as potential candidates. This cytokine has received a great deal of interest of late as it cannot suppress apoptosis and induce DNA synthesis in a manner similar to PPs.[95]


 » Conclusion Top


The PPAR family of nuclear receptors functions to regulate a broad range of genes in many metabolically active tissues. The PPARg agonists have demonstrated insulin sensitising and glucose regulating activity, whereas PPARa agonists have lipid/ cholesterol modulating properties. In addition, PPARd plays a significant role in various clinical disorders but its exact physiological importance needs to be elucidated. These receptors participate in the systemic regulation of lipid metabolism acting as sensors for fatty acids, eicosanoids, prostaglandins and related metabolites. PPARs are found to be critical regulators of inflammatory responses, not only through metabolic effects, but also through their direct actions on vascular and inflammatory cells.

These observations point to the fact that PPARs have a therapeutic role in limiting atherosclerosis or its complications. Although, PPARs have emerged as therapeutic targets in treating diabetes and cardiovascular diseases, additional insight into the role of these intrigued receptors in other diseases remains an area of active research. The amount and breadth of research efforts devoted to these proteins ensures that more discoveries are certain to emerge.

 
 » References Top

1.Willson TM, Brown PJ, Sternbach DD, Henke BR. The PPARs: From orphan receptors to drug discovery. J Med Chem 2000;43:527-50.  Back to cited text no. 1    
2.Kersten S, Wahli W. New Approaches to Drug Development. Jolles P, editors. Switzerland: Birkhauser Verlag; 2000.  Back to cited text no. 2    
3.Shearer BG, Hoekstra WJ. Recent advances in peroxisome proliferator-activated receptor science. Curr Med Chem 2003;10:267-80.  Back to cited text no. 3  [PUBMED]  [FULLTEXT]
4.Plutzky J. The potential role of Peroxisome Proliferator-Activated Receptors on inflammation in type 2 diabetes mellitus and atherosclerosis. Am J Cardiol 2003;92:34-41.  Back to cited text no. 4  [PUBMED]  [FULLTEXT]
5.Rosen ED, Spiegelman BM. PPARg: a nuclear regulator of metabolism, differentiation and cell growth. J Bio Chem 2001;276:37731-4.  Back to cited text no. 5  [PUBMED]  [FULLTEXT]
6.Marx N, Sukhova GK, Collins T, Libby P, Plutzky J. PPARa activators inhibit cytokine induced vascular cell adhesion molecule: 1 expression in human endothelial cells. Circulation 1999;99:3125-31.  Back to cited text no. 6  [PUBMED]  [FULLTEXT]
7.Spencer NF, Poynter ME, Im SR, Daynes RA. Constitutive activation of NF-kappaB in an animal model of aging. Int Immunol 1997;9:1581-8.  Back to cited text no. 7    
8.Chinetti G, Griglio S, Antonucci M, Torra IP, Delerive P, Majd Z, et al. Activation of PPARa and g induces apoptosis of human monocyte derived macrophages. J Biol Chem 1998;273:25573-80.  Back to cited text no. 8    
9.Kota BP, Huang TH, Roufogalis BD. An overview on biological mechanisms of PPARs. Pharmacol Res 2005;51:85-94.  Back to cited text no. 9  [PUBMED]  [FULLTEXT]
10.Sher T, Yi HF, McBride OW, Gonzalez FJ. cDNA cloning chromosomal mapping and functional characterization of the human PPAR. Biochemistry 1993; 32:5598-604.  Back to cited text no. 10  [PUBMED]  
11.Brown PJ, Winegar DA, Plunket KD, Moore LB, Lewis MC, Wilson JG, et al . An Ureido-thioisobutyric acid (GW9578) is a subtype selective PPARa agonist with potent lipid-lowering activity. J Med Chem 1999; 42:3785-8.  Back to cited text no. 11    
12.Xu HE, Stanley TB, Montana VG, Lambert MH, Shearer BG, Cobb JE, et al . Structural basis for antagonist-mediated recruitment of nuclear co-repressors by PPARg. Nature 2002;415:813-7.  Back to cited text no. 12    
13.Singh JP, Kauffman R, Bensch W, Wang G, McClelland P, Bean J, et al . Identification of a novel selective PPARa agonist 2-methyl-2-(4-{3-[1-(4-methylbenzyl)-5-oxo-4,5-dihydro-1H-1,2,4-triazol-3-yl]propyl}phenoxy) propanoic acid (LY518674) that produces marked changes in serum lipids and apolipoprotein A-1 expression. Mol Pharmacol 2005; 68;763-8.   Back to cited text no. 13    
14.Issemann I, Green S. Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators. Nature 1990; 347:645-50.  Back to cited text no. 14  [PUBMED]  [FULLTEXT]
15.Ross SD, Allen IE, Connelly JE, Korenblat BM, Smith ME, Bishop D, et al . Clinical outcomes in statin treatment trials: A meta-analysis. Arch Intern Med 1999;159:1793-802.  Back to cited text no. 15    
16.Staels B, Dallongeville J, Auwerx J, Schoonjans K, Leitersdorf E, Fruchart JC. Mechanism of action of fibrates on lipid and lipoprotein metabolism. Circulation 1998;98:2088-93.  Back to cited text no. 16  [PUBMED]  [FULLTEXT]
17.Ide T, Shimano H, Yoshikawa T, Yahagi N, Kudo MA, Matsuzaka T, et al . Cross-talk between peroxisome proliferator-activated receptor (PPAR) a and liver X receptor (LXR) in nutritional regulation of fatty acid metabolism. II. LXRs suppress lipid degradation gene promoters through inhibition of PPAR signaling. Mol Endo 2003;17:1255-67.  Back to cited text no. 17    
18.Anderson SP, Dunn C, Laughter A, Yoon L, Swanson C, Stulnig TM, et al . Overlapping transcriptional programs regulated by the nuclear receptors peroxisome proliferators activated receptor a, retinoid X receptor and liver X receptor in mouse liver. Mol Pharmacol 2004;66:1440-52.  Back to cited text no. 18    
19.Cabrero A, Llaverias G, Roglans N, Alegret M, Sanchez R, Adzet T, et al . Uncoupling protein-3 mRNA levels are increased in white adipose tissue and skeletal muscle of bezafibrate-treated rats. Biochem Biophys Res Commun1999;260:547-56.   Back to cited text no. 19    
20.Krook A, Digby J, O'Rahilly S, Zierath JR, Henriksson WH. Uncoupling protein 3 is reduced in skeletal muscle of NIDDM patients. Diabetes 1998;47: 1528-31.  Back to cited text no. 20    
21.Etgen GJ, Oldham BA, Johnson WT, Broderick CL, Montrose CR, Brozinick JT, et al . A tailored therapy for the metabolic syndrome: The dual Peroxisome Proliferator-Activated Receptor-a/g agonist LY465608 ameliorates insulin resistance and diabetic hyperglycemia while improving cardiovascular risk factors in preclinical models. Diabetes 2002;51:1083-7.  Back to cited text no. 21    
22.Brooks DA, Etgen GJ, Rito CJ, Shuker AJ, Dominianni SJ, Warshawsky AM, et al . Design and synthesis of 2-methyl-2-[4-(2-[5-methyl-2-aryloxazol-4-yl]ethoxy)phenoxy]propionic acids: a new class of dual PPARa/g agonists. J Med Chem 200;44:2061-4.  Back to cited text no. 22    
23.Mukherjee R, Jow L, Croston GE, Paterniti JR. Identification, characterization and tissue distribution of human peroxisome proliferator-activated receptor (PPAR) isoforms PPARg2 versus PPARg1 and activation with retinoid X receptor agonists and antagonists. J Biol Chem 1997; 272,8071-6.  Back to cited text no. 23    
24.Spiegelman BM, Flier JS. Identification, characterization, and tissue distribution of human PPAR isoforms PPARg2 versus PPARg1 and activation with retinoid X receptor agonists and antagonists. Curr Opin Cell Biol 1996;87: 377-89.  Back to cited text no. 24  [PUBMED]  [FULLTEXT]
25.Henke BR, Blanchard SG, Brackeen MF, Brown KK, Cobb JE, Collins JL, et al . N- (2-Benzoylphenyl)-l-tyrosine PPARg agonists. 1. Discovery of a novel series of potent antihyperglycemic and antihyperlipidemic agents. J Med Chem 1998;41:5020-36.  Back to cited text no. 25    
26.Collins JL, Blanchard SG, Boswell GE, Charifson PS, Cobb JE, Henke BR, et al . N-(2-Benzoylphenyl)-l-tyrosine PPARg agonists. 2. Structure-activity relationship and optimization of the phenyl alkyl ether moiety. J Med Chem 1998;41:5037-54.  Back to cited text no. 26    
27.Cobb JE, Blanchard SG, Boswell GE, Brown KK, Charifson PS, Cooper JP, et al . N-(2-Benzoylphenyl)-l-tyrosine PPARg agonists. 3. Structure-activity relationship and optimization of the N-aryl substituent. J Med Chem 1998;41: 5055-69.  Back to cited text no. 27    
28.Shinkai H, Onogi S, Tanaka M, Shibata T, Iwao M, Wakitani K, et al . Isoxazolidine-3,5-dione and noncyclic 1,3-Dicarbonyl compounds as hypoglycemic agents. J Med Chem 1998;41:1927-33.  Back to cited text no. 28    
29.Murakami K, Tobe K, Ide T, Mochizuki T, Ohashi M, Akanuma Y, et al . A novel insulin sensitizer acts as a coligand for Peroxisome Proliferator-Activated Receptor a (PPARa) and PPARg: Effect of PPARa activation on abnormal lipid metabolism in liver of Zucker fatty rats. Diabetes 1998;47:1841-7.   Back to cited text no. 29    
30.Oberfield JL, Collins JL, Holmes CP, Goreham DM, Cooper JP, Cobb JE, et al . A Peroxisome Proliferator-Activated Receptor g ligand inhibits adipocyte differentiation. Prac Natl Aca Sci USA 1999;96:6102-6.   Back to cited text no. 30    
31.Willson TM, Lambert MH, Kliewer SA. Peroxisome Proliferator-Activated Receptor g and metabolic disease. Ann Rev Biochem 2001;70:341-67.  Back to cited text no. 31  [PUBMED]  [FULLTEXT]
32.Reginato MJ, Bailey ST, Krakow SL, Minami C, Ishii S, Tanaka H, et al . A potent antidiabetic thiazolidinedione with unique Peroxisome Proliferator-Activated Receptor g-activating properties. J Biol Chem 1998;273: 32679-84.  Back to cited text no. 32    
33.Fukui Y, Masui S, Osada S, Umesono K, Motojima K. A new thiazolidinedione, NC-2100, which is a weak PPARg activator, exhibits potent antidiabetic effects and induces uncoupling protein 1 in white adipose tissue of KKAy obese mice. Diabetes 2000;49:759-67.   Back to cited text no. 33  [PUBMED]  [FULLTEXT]
34.Miyahara T, Schrum L, Rippe R, Xiong S, Yee Hal F Jr, Motomura K, et al . Peroxisome Proliferator-Activated Receptors and hepatic stellate cell activation. J Biol Chem 2000;275:35715-22.   Back to cited text no. 34    
35.Huang JT, Welch JS, Ricote M, Binder CJ, Willson TM, Kelly C, et al . Interleukin-4-dependent production of PPARg ligands in macrophages by 12/15-lipoxygenase. Nature 1999;400:378-82.  Back to cited text no. 35    
36.Lee G, Elwood F, McNally J, Weiszmann J, Lindstrom M, Amaral K, et al . T0070907, a selective ligand for Peroxisome Proliferator-Activated Receptor g, functions as an antagonist of biochemical and cellular activities. J Biol Chem 2002; 277:19649-57.   Back to cited text no. 36    
37.Camp HS, Chaudhry A, Leff T. A Novel potent antagonist of Peroxisome Proliferator-Activated Receptor g blocks adipocyte differentiation but does not revert the phenotype of terminally differentiated adipocytes. Endocrinology 2001;142:3207-13.   Back to cited text no. 37  [PUBMED]  [FULLTEXT]
38.Mukherjee R, Hoener PA, Jow L, Bilakovics J, Klausing K, Mais DE, et al . A selective Peroxisome Proliferator-Activated Receptor-{gamma} (PPAR {gamma}) modulator blocks adipocyte Differentiation but stimulates glucose uptake in 3T3-L1 adipocytes. Mol Endocrinol 2000;14:1425-33.   Back to cited text no. 38    
39.Grossman SL, Lessem J. Mechanisms and clinical effects of thiazolidinediones. Expert Opin Invest Drugs 1997;6:1025-40.  Back to cited text no. 39  [PUBMED]  
40.Ikeda H, Taketomi S, Sugiyama Y, Shimura Y, Sohda T, Meguro K, et al . Effects of Pioglitazone on glucose and lipid metabolism on normal and insulin resistant animals. Arzneimittelforschung 1990;40,156-62.   Back to cited text no. 40    
41.Rangwala SM, Lazar MA. Peroxisome Proliferators-Activated Receptor g in diabetes and metabolism. Trends Pharmacol Sci 2004;25:331-6.  Back to cited text no. 41  [PUBMED]  [FULLTEXT]
42.Berger JP, Akiyama TE, Meinke PT. PPARs: Therapeutic targets for metabolic disease. Trends Pharmacol Sci 2005;26:244-51.   Back to cited text no. 42  [PUBMED]  [FULLTEXT]
43.Hallakou S, Doarι L, Foufelle F, Kergoat M, Guerre-Millo M, et al . Pioglitazone induces in vivo adipocyte differentiation in the obese Zucker fa / fa rat. Diabetes 1999;46:1393-9.  Back to cited text no. 43    
44.Okuno A, Tamemoto H, Tobe K, Ueki K, Mori Y, Iwamoto K, et al . Troglitazone increases the number of small adipocytes without the change of white adipose tissue mass in obese zucker rats. J Clin Invest 1998;101:1354-61.  Back to cited text no. 44    
45.Tontonoz P, Nagy L, Alvarez JGA, Thomazy VA, Evans RM. A PPARg promotes monocyte/macrophage differentiation and uptake of oxidized LDL. Cell 1998;93:241-52.   Back to cited text no. 45    
46.Li AC, Brown KK, Silvestre MJ, Willson TM, Palinski W, Glass CK. Peroxisome Proliferator-Activated Receptor g ligands inhibit development of atherosclerosis in LDL receptor deficient mice. J Clin Invest 2000;106:523-31.  Back to cited text no. 46  [PUBMED]  [FULLTEXT]
47.Tontonoz P, Singer S, Forman BM, Sarraf P, Fletcher JA, Fletcher CD, et al . Terminal differentiation of human liposarcoma cells induced by ligands for Peroxisome Proliferator-Activated Receptor g and the retinoid X receptor. Proc Natl Acad Sci USA 1997;94:237-41.  Back to cited text no. 47    
48.Minamikawa J, Yamauchi M, Inoue D, Koshiyama H. Another potential use of troglitazone in noninsulin dependent diabetes mellitus. J Clin Endocrinol Metab 1998;83:1041-2.  Back to cited text no. 48  [PUBMED]  [FULLTEXT]
49.Repa JJ, Turley SD, Lobaccaro MA, Medina J, Li L, Lustig K, et al . Regulation of absorption and ABC1 mediated efflux of cholesterol by RXR heterodimers. Science 2000;289:1524-9.  Back to cited text no. 49    
50.Chawla A, Boisvert WA, Lee CH, Laffitte BA, Barak Y, Joseph SB, et al . A PPAR gamma-LXR-ABCA1 pathway in macrophages is involved in cholesterol efflux and atherogenesis. Mol Cell 2001;7:161-71.  Back to cited text no. 50    
51.Staels B. PPARg & atherosclerosis. Curr Med Res Opin 2005;21:13-20.  Back to cited text no. 51    
52.Debril MB, Renaud JP, Fajas L, Auwerx J. The pleiotropic functions of Proxisome Poliferator-Ativated Rceptor g. J Mol Med 2001;79:30-47.  Back to cited text no. 52    
53.Gelman L, Fruchart JC, Auwerx J. An update on the mechanisms of action of the Peroxisome Proliferator-Activated Receptors (PPARs) and their roles in inflammation and cancer. Cell Mol Life Sci 1999;55:932-43.  Back to cited text no. 53    
54.Jiang C, Ting AT, Seed B. PPARg agonists inhibit production of monocyte inflammatory cytokines. Nature 1998;391:82-6.  Back to cited text no. 54    
55.Ricote M, Huang JT, Welch JS, Glass CK. The Peroxisome Proliferator- Activated Receptor g (PPARg) as a regulator of monocyte/macrophage function. J Leukoc Biol 1999;66:733-9.   Back to cited text no. 55    
56.Cuzzocrea S, Pisano B, Dugo L, Ianaro A, Maffia P, Patel NS, et al . Rosiglitazone, a ligand of the peroxisome proliferator-activated receptor-g reduces acute inflammation. Eur J Pharmacol 2004;483:79-93.  Back to cited text no. 56    
57.Collins AR, Meechan WP, Kintscher U, Jackson S, Wakino S, Noh G, et al . Troglitazone inhibits formation of early atheroscerotic lesions in diabetic and nondiabetic low-density lipoprotein receptor-deficient mice. Arterioscler Thromb Vasc Biol 2001;21:365-71.  Back to cited text no. 57    
58.Mueller E, Sarraf P, Tontonoz P, Evans RM, Martin KJ, Zhang M, et al . Terminal differentiation of human breast cancer through PPAR gamma. Mol Cell 1998;1:465-70.  Back to cited text no. 58    
59.Sarraf P, Mueller E, Jones D, King FJ, DeAngelo DJ, Partridge JB, et al . Differentiation and reversal of malignant changes in colon cancer through PPARd. Nat Med 1998;4:1046-52.  Back to cited text no. 59    
60.Chang TH, Szabo E. Induction of differentiation and apoptosis by ligands of Peroxisome Proliferator-Activated Receptor g in non small cell lung cancer. Cancer Res 2000;60:1129-38.  Back to cited text no. 60    
61.Tsubouchi Y, Sano H, Kawahito Y, Mukai S, Yamada R, Kohno M, et al . Inhibition of human lung cancer cell growth by the Peroxisome Proliferator-Activated Receptor g agonists through induction of apoptosis. Biochem Biophys Res Commun 2000;270:400-5.  Back to cited text no. 61    
62.Kubota T, Koshizuka K, Williamson EA, Asou H, Said JW, Holden S, et al . Ligand for Peroxisome Proliferator-Activated Receptor g (troglitazone) has potent anti-tumor effect against human prostate cancer both in vitro and in vivo . Cancer Res 1998;58:3344-52.   Back to cited text no. 62    
63.Guan YF, Zhang YH, Breyer RM, Davis L, Breyer MD. Expression of Peroxisome Proliferator-Activated Receptor g (PPARg) in human transitional bladder cancer and its role in inducing cell death. Neoplasia 1999;1:330-9.  Back to cited text no. 63    
64.Takahashi GN, Okumura T, Motomura W, Fujimoto Y, Kawabata I, Kohgo Y, et al . Activation of PPARg inhibit cell growth and induce apoptosis in human gastric cancer cells. FEBS Lett 1999;455:135-9.  Back to cited text no. 64    
65.Murphy GJ, Holder JC. PPARg agonists: Therapeutic role in diabetes, inflammation and cancer. Trends Pharmacol Sci 2000;21:469-74.  Back to cited text no. 65    
66.Roberts-Thomson SJ. Peroxisome Proliferator-Activated Receptors in tumorigenesis: Targets of tumor promotion and treatment. Immunol Cell Biol 2000; 78:436-41.  Back to cited text no. 66    
67.Demetri GD, Fletcher CDM, Mueller E, Sarraf P, Naujoks R, Campbell N, et al . Induction of solid tumor differentiation by the Peroxisome Proliferator-Activated Receptor ligand troglitazone in patients with liposarcoma. Proc Natl Acad Sci USA 1999; 96:3951-6.  Back to cited text no. 67    
68.Schmidt A, Endo N, Rutledge SJ, Vogel R, Shinar D, Rodan GA. Identification of a new member of the steroid hormone receptor superfamily that is activated by a peroxisome proliferator and fatty acids. Mol Endocrinol 1992;6:1634-41.  Back to cited text no. 68    
69.Oliver WR, Shenk JL, Snaith MR, Russell CS, Plunket K, Bodkin NL, et al . A selective Peroxisome Proliferator-Activated Receptor d agonist promotes reverse cholesterol transport. Proc Natl Acad Sci USA 2001;98:5306-11.  Back to cited text no. 69    
70.Hansen JB, Zhang H, Rasmussen TH, Petersen RK, Flindt EN, Kristiansen K. Peroxisome Proliferator-Activated Receptor g (PPARg)-mediated regulation of preadipocyte proliferation and gene expression is dependent on cAMP signalling. J Biol Chem 2001;276:3175-82.  Back to cited text no. 70    
71.He TC, Chan TA, Vogelstein B, Kinzler KW. PPARd is an APC-regulated target of nonsteroidal anti-inflammatory drugs. Cell 1999;99:335-45.  Back to cited text no. 71    
72.Mano H, Kimura C, Fujisawa Y, Kameda T, Watanabe-Mano M, Kaneko H, et al . Cloning and function of rabbit Peroxisome Proliferator-Activated Receptor d/β in mature osteoclasts. J Biol Chem 2000;275:8126-32.  Back to cited text no. 72    
73.Lim H, Gupta RA, Ma WG, Paria BC, Moller DE, Morrow ID, et al . Cyclo-oxygenase-2-derived prostacyclin mediates embryo implantation in the mouse via PPARd. Genes Dev 1999;13:1561-74.  Back to cited text no. 73    
74.Peters JM, Lee SS, Li W, Ward JM, Gavrilova O, Everett C, et al . Growth, adipose, brain, and skin alterations resulting from targeted disruption of the mouse Peroxisome Proliferator-Activated Receptor g(d). Mol Cell Biol 2000;20:5119-28.   Back to cited text no. 74    
75.Michalik L, Desvergne B, Tan NS, Modak BS, Escher P, Rieusset J, et al . Impaired skin wound healing in Peroxisome Proliferator-Activated Receptor (PPAR)a and PPARβ mutant mice. J Cell Biol 2001;154:799-814.   Back to cited text no. 75    
76.Chao EY, Haffiner CD, Lamber MH, Maloney PR, inventor; Glaxo Group Ltd., assignee. Thiazole and oxazole derivatives and their pharmaceutical use. PCT. International Patent Application WO0100603. 2001 Apl 1.  Back to cited text no. 76    
77.Berger J, Leibowitz MD, Doebber TW, Elbrecht A, Zhang B, Zhou G, et al . Novel Peroxisome Proliferator-Activated Receptor (PPAR) g and PPARd Ligands produce distinct biological effects. J Biol Chem 1999;274:6718-25.  Back to cited text no. 77    
78.Leibowitz MD, Berger JP, Moller DE, Auwerx J, inventor; Merck & Co. Inc., assignee. Methods for raising HDL cholesterol levels. PCT. International Patent Application WO9728149. 1997 Jul 8.  Back to cited text no. 78    
79.Leibowitz MD, Fievet C, Hennuyer N, Peinado-Onsurbe J, Duez H, Bergera J, et al . Activation of PPARd alters lipid metabolism in db/db mice. FEBS Lett 2000;473:333-6.  Back to cited text no. 79    
80.DuBois RN, Giardiello FM, Smalley WE. Nonsteroidal anti-inflammatory drugs, eicosanoids, and colorectal cancer prevention. Gastroenterol Clin North Am 1996;25:773-91.  Back to cited text no. 80    
81.Park BH, Vogelstein B, Kinzler KW. Genetic disruption of PPARd decreases the tumorigenicity of human colon cancer cells. Proc Natl Acad Sci USA 2001;98:2598-603.  Back to cited text no. 81    
82.Jackson SM, Demer LL. Peroxisome Proliferator-Activated Receptor activators modulate the osteoblastic maturation of MC3T3-E1 preosteoblasts. FEBS Lett 2000;471:119-24.   Back to cited text no. 82    
83.Ehrmann J Jr, Vavrusova N, Collon Y, Kolar Z. Peroxisome Proliferators-Activated Receptors (PPARs) in health and disease. Biomed Papers 2002;146:11-14.  Back to cited text no. 83    
84.Pershadsingh HA, Heneka MT, Saini R, Amin NM, Broeske DJ, Feinstein DL. Effect of pioglitazone treatment in a patient with secondary multiple sclerosis. J Neuroinflammation 2004;1:3.  Back to cited text no. 84    
85.Saluja I, Granneman JG, Skoff RP. PPARd agonists stimulate oligodendrocyte differentiation in tissue culture. Glia 2001;33:191-204.  Back to cited text no. 85    
86.Lohray, BB, Lohray VB, Bajji AC, Kalchar S, Poondra RR, Padakanti S, et al . (-)3-[4-[2-(Phenoxazin-10-yl)ethoxy]phenyl]-2-ethoxypropanoic acid [(-)DRF 2725]: A dual PPAR agonist with potent antihyperglycemic and lipid modulating activity. J Med Chem 2001;44:2675-8.  Back to cited text no. 86    
87.Nissen SE, Wolski K, Topol EJ. Effect of Muraglitazar on death and major adverse cardiovascular events in patients with type 2 diabetes mellitus. JAMA 2005;294:2581-6.  Back to cited text no. 87    
88.Reifel-Miller A, Otto K, Hawkins E, Barr R, Bensch WR, Bull C, et al . A Peroxisome Proliferator-Activated Receptor a/g dual agonist with a unique in vitro profile and potent glucose and lipid effects in rodent models of type 2 diabetes and dyslipidemia. Mol Endocrinol 2005;19:1593-605.  Back to cited text no. 88    
89.Scaeffer S. Trying to beat PPAR. [Cited 2004 Jun 14]. Available from: http://www.biocentury.com.  Back to cited text no. 89    
90.Willson TM, Cobb JE, Cowan DJ, Wiethe RW, Correa ID, Prakash SR, et al . The structure-activity relationship between Peroxisome Proliferator Receptor g agonism and the antihyperglycemic activity of thiazolidinediones. J Med Chem 1996;39:665-8.   Back to cited text no. 90    
91.Galida-Dual PPAR agonist for type 2 diabetes and metabolic syndrome. Available from: http://www.drugdevelopment-technology.com  Back to cited text no. 91    
92.Tenenbaum A, Motro M, Fisman EZ. Dual and Pan-Peroxisome Proliferator-Activated Receptors (PPAR) co-agonism: The bezafibrate lessons. Cardiovasc Diabetol 2005;4:14.  Back to cited text no. 92    
93.Perlecan Pharma's DRL 11605 enters Phase I clinical trials. Available from: http://www.expresspharmaonline.com.  Back to cited text no. 93    
94.Scheen AJ. Thiazolidinediones and liver toxicity. Diabetes Metab 2001;27: 305-13.  Back to cited text no. 94    
95.Holden PR, Tugwood JD. Peroxisome Proliferator-Activated Receptor alpha: role in rodent liver cancer and species differences. J Mol Endocrinol 1999; 22:1-8.  Back to cited text no. 95    


    Figures

[Figure - 1]

    Tables

[Table - 1], [Table - 2], [Table - 3]

This article has been cited by
1 Thiazolidine-2,4-dione Derivatives: Programmed Chemical Weapons for Key Protein Targets of Various Pathological Conditions
Navriti Chadha,Malkeet Singh Bahia,Maninder Kaur,Om Silakari
Bioorganic & Medicinal Chemistry. 2015;
[Pubmed] | [DOI]
2 The discovery of novel isoflavone pan peroxisome proliferator-activated receptor agonists
Azadeh Matin,Munikumar Reddy Doddareddy,Navnath Gavande,Srinivas Nammi,Paul W. Groundwater,Rebecca H. Roubin,David E. Hibbs
Bioorganic & Medicinal Chemistry. 2013; 21(3): 766
[Pubmed] | [DOI]
3 Thiazolidine-2,4-diones: Progress towards multifarious applications
Viral S. Jain,Dhagash K. Vora,C.S. Ramaa
Bioorganic & Medicinal Chemistry. 2013; 21(7): 1599
[Pubmed] | [DOI]
4 Models for the prediction of PPARs agonistic activity of indanylacetic acids
Rohit Dutt,A. K. Madan
Medicinal Chemistry Research. 2013; 22(7): 3213
[Pubmed] | [DOI]
5 Potential target sites to modulate vascular endothelial dysfunction: Current perspectives and future directions
Pitchai Balakumar,Tajpreet Kaur,Manjeet Singh
Toxicology. 2008; 245(1-2): 49
[Pubmed] | [DOI]
6 Potential target sites to modulate vascular endothelial dysfunction: Current perspectives and future directions
Balakumar, P., Kaur, T., Singh, M.
Toxicology. 2008; 245((1-2)): 49-64
[Pubmed]
7 PPAR dual agonists: Are they opening Pandoraęs Box?
Balakumar, P., Rose, M., Ganti, S.S., Krishan, P., Singh, M.
Pharmacological Research. 2007; 56(2): 91-98
[Pubmed]
8 PPAR ligands: Are they potential agents for cardiovascular disorders?
Balakumar, P., Rose, M., Singh, M.
Pharmacology. 2007; 80(1): 1-10
[Pubmed]
9 Peroxisome Proliferator Activated Receptor Agonists: Emerging Therapy for Cardiovascular Complications
Pitchai Balakumar ., Madhankumar Rose ., Manjeet Singh .
Journal of Pharmacology and Toxicology. 2007; 2(3): 205
[VIEW] | [DOI]
10 Evolution of peroxisome proliferator-activated receptor agonists
Chang, F., Jaber, L.A., Berlie, H.D., OęConnell, M.B.
Annals of Pharmacotherapy. 2007; 41(6): 973-983
[Pubmed]
11 PPAR Ligands: Are They Potential Agents for Cardiovascular Disorders?
Pitchai Balakumar,Madhankumar Rose,Manjeet Singh
Pharmacology. 2007; 80(1): 1
[Pubmed] | [DOI]
12 Prevention of type 2 diabetes mellitus - Current opportunities
Zełobowska, K., Gumprecht, J., Simońska-Cichocka, E., Zywiec, J., Skubala, A., Grzeszczak, W.
Diabetologia Doswiadczalna i Kliniczna. 2007; 7(4): 161-167
[Pubmed]
13 Rhodanine derivatives as novel peroxisome proliferator-activated receptor γ agonists
Liu, Q., Zhang, Y.-Y., Lu, H.-L., Li, Q.-Y., Zhou, C.-H., Wang, M.-W.
Acta Pharmacologica Sinica. 2007; 28(12): 2033-2039
[Pubmed]
14 PPARs, metabolic syndrome and cancer
Tang, C.-C., Chieh, K., Chen, T.-S., Hsu, S.-Y.
Journal of Internal Medicine of Taiwan. 2007; 18(5): 244-255
[Pubmed]



 

Top
Print this article  Email this article

    

Site Map | Home | Contact Us | Feedback | Copyright and Disclaimer
Online since 20th July '04
Published by Wolters Kluwer - Medknow